PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
3.68
P/E exceeding 1.5x Medical - Pharmaceuticals median of 1.67. Michael Burry would check for market euphoria. Scrutinize growth expectations.
0.39
P/S less than half the Medical - Pharmaceuticals median of 4.36. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
No Data
No Data available this quarter, please select a different quarter.
37.85
Positive FCF while Medical - Pharmaceuticals median shows negative FCF. Peter Lynch would examine cash flow generation advantage.
12.23
Positive operating cash flow while Medical - Pharmaceuticals median is negative. Peter Lynch would examine operational advantage.
No Data
No Data available this quarter, please select a different quarter.
6.79%
Earnings yield exceeding 1.5x Medical - Pharmaceuticals median of 0.90%. Joel Greenblatt would investigate if high yield reflects hidden value.
2.64%
Positive FCF while Medical - Pharmaceuticals median shows negative FCF. Peter Lynch would examine cash generation advantage.